CHENGDU, China, April 5, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) (“Keymed” or the “Company”) today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its […]
CHENGDU, China, April 5, 2025 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) (“Keymed” or the “Company”) today announced that the prestigious medical journal Nature Medicine has published the results from the Phase III trial of its […]